Teva has announced that its Trisenox (arsenic trioxide) injection has been awarded US approval from the FDA in combination with tretinoin for the treatment of newly-diagnosed low-risk acute promyelocytic leukaemia (APL) in adult patients whose APL is characterised by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
FDA expands indication of Teva’s Trisenox for acute promyelocytic leukaemia
